Tensions between tech and tech media escalated over the weekend, in a vitriolic back-and-forth that mostly took place on Twitter and new voice chat app Clubhouse.

Axios Re:Cap digs into why the relationship has soured with Jason Calacanis, who has been on both sides of the tech/media divide.

Go deeper

Tech jobs aren't immune to the coronavirus

Illustration: Aïda Amer/Axios

It's not just lower-wage service jobs in retail and at restaurants anymore. The effects of the coronavirus are beginning to reach the seemingly impervious tech industry.

By the numbers: New data from the jobs site Indeed shows that tech job postings were down 36% in late July, compared with the same time last year. That's even worse than the overall year-over-over drop in job postings of 21%.

Pelosi, Schumer demand postmaster general reverse USPS cuts ahead of election

Schumer and Pelosi. Photo: Alex Wong/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Minority Leader Chuck Schumer sent a letter to Postmaster General Louis DeJoy on Thursday calling for the recent Trump appointee to reverse operational changes to the U.S. Postal Service that "threaten the timely delivery of mail" ahead of the 2020 election.

Why it matters: U.S. mail and election infrastructure are facing a test like no other this November, with a record-breaking number of mail-in ballots expected as Americans attempt to vote in the midst of a pandemic.

CRISPR co-discoverer on the gene editor's pandemic push

Photo illustration: Aïda Amer/Axios. Photos: Brian Ach/Getty Images for Wired and BSIP/UIG via Getty Images

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease — and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR — which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing — are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.